XLO Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research - Mentions: IMTX

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

2 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

2 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

3 days ago - By: Zacks Investment Research - Mentions: BTAI

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

4 days ago - By: Benzinga - Mentions: SGMO NNVC REVB CYCN ...

12 Health Care Stocks Moving In Monday's After-Market Session

2 months ago - By: Stocktwits - Mentions: GILD

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

8 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

8 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

8 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

8 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

11 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

16 days ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

2 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

3 months ago - By: Zacks Investment Research - Mentions: MGTX

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: The Motley Fool - Mentions: GILD

Xilio Revenue Jumps 246 Percent in Q2

3 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

3 months ago - By: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

3 months ago - By: Yahoo Finance - Mentions: WFC UBS MNDY CACI ...

Snap downgraded, Leidos upgraded: Wall Street's top analyst calls

3 months ago - By: Catalyst Pharmaceuticals, Inc. - Mentions: CPRX

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

4 months ago - By: Xilio Therapeutics, Inc.